Sponsor
- Home
- Your Messages
-
Smartest Doc
Daily Quiz CompetitionTest your clinical knowledge against other physicians in the USA by taking our FREE daily quiz!
New! PHYSICIAN REVIEW
Thousands of questions to assess your knowledge and aid exam prep!
- Physician Jobs (1014)
- More
- Other Specialty
Pneumococcal 13-valent conjugate vaccine (Prevnar 13): A pneumococcal polysaccharide conjugated to carrier protein diphtheria CRM197 for the prevention of pneumonia and invasive pneumococcal disease in adults aged 50+ years
Formulary , 04/04/2012
Pneumococcal 13–valent conjugate vaccine (Prevnar 13) was granted accelerated FDA marketing approval for the prevention of pneumonia and invasive disease (infection of blood or spinal fluid) caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults age 50 years and older. Prevnar 13 was previously approved for use in children aged 6 weeks through 5 years for the prevention of invasive disease caused by 13 different serotypes of S. pneumoniae and for the prevention of otitis media caused by 7 of the serotypes of the bacterium.
Register now to view all the MDLinx contents (FREE)!
- Stay current on the latest literature, research and clinical news
- Get special communications and offers from MDLinx and our sponsors
- Receive invitations to paid market research
Login
Sponsor
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close
Sponsor